Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study
Introduction
Pneumocystis carinii has been recognized as a human pathogen for nearly 50 years. It remains an important cause of morbidity and mortality in immunocompromised patients. Although Pneumocystis carinii pneumonia (PCP) is frequently associated with acquired immunodeficiency syndrome (AIDS), several groups of non-AIDS immunocompromised patients are also at risk of PCP.1., 2., 3., 4. As we previously reported patients with hematologic malignancies are particularly at risk for this opportunistic infection.5 On the one hand the use of new chemotherapies which induce prolonged and deep immunosuppression might increase the risk of PCP. On the other hand, new diagnosis procedures could explain the apparent increasing frequency in these patients. Moreover, despite the suggestion that the frequency of PCP might be increasing in patients with hematologic malignancies,6 only a few data are available to determine clinical risk factors or biological parameters which could led to propose primary prophylaxis.
This prompted us to focus on the cases of PCP which occurred in HIV-negative adults suffering from hematologic diseases, over a five year period (1995–1999) in the infectious diseases units involved in our research group (GERICCO, Groupe d'Etudes et de Recherche en Infectiologie Clinique du Centre Ouest). The aims of the study were to determine which are the underlying hematologic malignancies associated to PCP, to precise serious signs which can lead patients to intensive care unit (ICU) and to assess prognosis factors for this opportunistic infection.
Section snippets
Patients and methods
We retrospectively, collected all cases of microbiologically documented PCP in HIV1/2 negative adults patients (over 18 years of age) with hematologic malignancies, between January 1995 and December 1999, in GERICCO centres. Patients were identified through a search of data compiled by mycology laboratories and clinical units in each centre. The diagnosis of PCP was proved, confirming the clinical suspicion, on the basis of microbiological evidence of P. carinii cysts in bronchoalveolar lavage
Results
The clinical and laboratory characteristics of 60 HIV-negative patients suffering from hematologic malignancies were recorded.
Patients’ age ranged between 22 and 79 years (mean value=59±14.5 years), and a prevalence of males (34, 56.7%) over females (26, 43.3%) was observed.
The number of patients with PCP admitted per year is shown in Figure 1. The lack of regional register did not allowed the incidence rate of PCP to be calculated for each group of hematologic malignancies. Underlying diseases
Discussion
The high incidence of PCP in AIDS patients has focused clinical and laboratory research on understanding the biology of the organism and on improving diagnosis, treatment and prevention of this disease. Issues related to the epidemiology, transmission and reactivation of P. carinii remain controversial. Epidemiological studies have suggested that P. carinii is communicable and that the airborne route seems to be the major mode of transmission.8., 9. Nevertheless, some data suggest that
Acknowledgements
We thank all our colleagues in GERICCO who sent us data about their patients: Prof. J. Achard, Dr J.M. Chennebeau, Prof. P. Choutet, Dr M. Dary, Dr J.A. Gandji, Prof. C. Michelet, Prof. M. Garré, Dr B. Garo, Dr Y. Guimard, Prof. E. Pichard.
References (44)
- et al.
Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia
Chest
(2001) - et al.
Update on the epidemiology and transmission of Pneumocystis carinii
Microbes Infect
(2002) - et al.
Molecular epidemiology of human pneumocystosis
Med Mal Inf
(1999) - et al.
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders
Ann Oncol
(2001) - et al.
Pneumocystis carinii pneumonia in cancer patients
Canc Treat Reviews
(1993) - et al.
Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia
Respir Med
(2001) - et al.
Use of adjunctive corticosteroids in severe adults non-HIV Pneumocystis carinii pneumonia
Chest
(1998) - et al.
Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia
Intern J Antimicrob Ag
(2001) - et al.
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
Lancet
(1999) - et al.
Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients HIV-1: a prospective study
Lancet
(2001)
Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
Biol Blood Marrow Transplant
Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis
Cancer
Pneumocystis carinii pneumonia among patients with neoplastic disease
Sem Resp infections
Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome
Arch Intern Med
Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome
Clin Infect Dis
Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients
Eur J Clin Microbiol Infect Dis
Pneumocystis carinii pneumonia in patients with cancer
Cancer
New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia
JAMA
The role of person-to-person transmission in an epidemiologic study of Pneumocystis carinii pneumonia
AIDS
Current issues in the epidemiology, transmission and reactivation of Pneumocystis carinii
Sem Resp Infections
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIGEMA centres
Br J Haematol
Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy
Ann Intern Med
Cited by (70)
Serial change in serum biomarkers during treatment of Non-HIV Pneumocystis pneumonia
2019, Journal of Infection and ChemotherapyCitation Excerpt :The prevalence of PCP has thus been increasing in patient groups other than HIV-infected patients [1]. Recent studies of the clinical characteristics, outcomes, and prognostic factors for non-HIV PCP and HIV PCP [2–27] indicate that these conditions differ in clinical manifestations and characteristics and prognosis. Non-HIV PCP tends to have a more rapid clinical course.
Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study
2018, Journal of Microbiology, Immunology and InfectionPneumocystis carinii pneumonia revealing diabetes mellitus
2016, Revue de Pneumologie CliniquePneumocystosis in non-HIV-infected immunocompromised patients
2016, Revue de Medecine InterneAll patients with leukemia are not equally at risk of contracting pneumocystis jirovecii pneumonia
2015, American Journal of Medicine
- 1
Groupe d'Etudes et de Recherche en Infectiologie Clinique du Centre Ouest